ScreenerHero

BOLT Bolt Biotherapeutics, Inc.

NAS · US · Healthcare · Biotechnology · boltbio.com
3.650USD+1.39%Mkt Cap: 7.03M $P/E: —

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that t…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap7.03M USD
Enterprise Value10.96M USD
Revenue (TTM)4.70M USD
Gross Profit-16.80M USD
Net Income (TTM)-33.38M USD
Revenue/Share2.68 USD
Last Price3.650 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.18
PEG—
EV/EBITDA-0.40
EV/Revenue2.33
P/S1.50
P/B0.56
EPS (TTM)-16.51
EPS (Forward)-20.19
52W Range
3.10013% of range7.200
52W High7.200 USD
52W Low3.100 USD
Profitability
Gross Margin0.00%
Oper. Margin-151320.00%
EBITDA Margin0.00%
Profit Margin-433.74%
ROE-125.92%
ROA-58.81%
Growth
Revenue Growth-99.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.85M USD
CapEx (TTM)72.00K USD
FCF Margin-399.83%
FCF Yield-267.27%
Net Debt4.03M USD
Net Debt/EBITDA-0.15
Balance Sheet
Debt/Equity0.87
Current Ratio2.61
Quick Ratio2.24
Book Value/Sh6.56 USD
Cash/Share9.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateJun 9, 2025
Analyst Consensus
Rating—
Target (Mean)29.00 USD
Upside (mean)+694.5%
Target Range5.000 USD – 75.00 USD
5.000+694.5% to mean75.00
# Analysts3
Ownership
Shares Out.1.93M
Float1.62M
Insiders3.46%
Institutions27.92%
Short Interest
Short Ratio0.8d
Short % Float0.96%
Short % Out.0.96%
Shares Short18.49K
Short (prev mo.)770
Technical
SMA 503.700 (-1.4%)
SMA 2004.559 (-19.9%)
Beta1.01
S&P 52W Chg15.84%
Avg Vol (30d)29.29K
Avg Vol (10d)16.30K
Technical Indicators
RSI (14)49.5
MACD-0.0661
MACD Signal-0.0710
MACD Hist.+0.0048
BB Upper3.981 USD
BB Middle3.650 USD
BB Lower3.320 USD
BB Width18.10%
ATR (14)0.2780 USD
Vol Ratio (20d)0.31x